Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the "miraculous" sodium-glucose co-transporter-2 inhibitors?

Patoulias, Dimitrios; Papadopoulos, Christodoulos; Kassimis, George; Doumas, Michael

Patoulias, Dimitrios; Papadopoulos, Christodoulos; Kassimis, George; Doumas, Michael.

Patoulias D; 2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece. dipatoulias@gmail.com.
Papadopoulos C; 3rd Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.
Kassimis G; 2nd Department of Cardiology, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.
Doumas M; 2nd Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital "Hippokration", Thessaloniki, Greece.

Kardiol Pol ; 79(9): 1048-1049, 2021.

Article in English | MEDLINE | ID: covidwho-1320652

Subject(s)

COVID-19; Cardiovascular Agents; Sodium-Glucose Transporter 2 Inhibitors; Symporters; Glucose; Humans; SARS-CoV-2; Sodium; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Agents / Symporters / Sodium-Glucose Transporter 2 Inhibitors / COVID-19 Type of study: Experimental Studies Limits: Humans Language: English Journal: Kardiol Pol Year: 2021 Document Type: Article Affiliation country: KP.a2021.0067

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google